Home › T-Cell Lymphoma › Maryland › Baltimore
T-Cell Lymphoma clinical trials in Baltimore, MD
4 studies for T-Cell Lymphoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RecruitingPhase 2
- University of Maryland/Greenebaum Cancer Center, Baltimore
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- University of Maryland Medical Center, Baltimore
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RecruitingPhase 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Johns Hopkins University, Baltimore
T-Cell Lymphoma trials in other cities
- New York City, NY12 studies
- Baldwin Park, CA10 studies
- Houston, TX9 studies
- Philadelphia, PA9 studies
- Atlanta, GA8 studies
- Boston, MA8 studies
- Chicago, IL6 studies
- Columbus, OH6 studies
- Rochester, MN6 studies
- Seattle, WA6 studies
- New Haven, CT5 studies
- Miami, FL5 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Prostate Cancer45 studies
- Breast Cancer44 studies
- Lung Cancer41 studies
- Cancer (all types)36 studies
- Colorectal Cancer30 studies
- Pancreatic Cancer30 studies
- Metastatic Cancer26 studies
- Obesity24 studies
- Bladder Cancer24 studies
- Ovarian Cancer23 studies
- Heart Failure23 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.